Anthony Cutts is a post-doctoral scientist based within the Oxford Molecular Diagnostic Centre. He received his BSc hons (Biochemistry) and MRes (Medical and Molecular Biosciences) at Newcastle University. Subsequently Anthony completed his D. Phil in Cell and Molecular Biology at the University of East Anglia, in a project part sponsored by AstraZeneca. The focus of this research was to use screening approaches for identifying proteins that play a role in regulating cell-signalling pathways and analysing the effects of their abnormal expression.
Anthony then joined Prof Anna Schuh’s research group at the University of Oxford, where he has a strong interest in translational research. He was heavily involved in the validation of a multi-gene cancer panel using Next Generation Sequencing (NGS), the first of its type to be implemented in the NHS. Currently, his main research focus is in cell free DNA (cfDNA) to identify somatic and constitutional variants as part of cancer and pre-natal diagnostics, respectively. This has involved developing new NGS protocols for the detection of circulating tumour DNA (ctDNA) across patients with different cancer types, where the clinical application is in early detection and identifying minimal residual disease. Furthermore, Anthony has a keen interest in circulating foetal free DNA (cffDNA), and is in the process of validating a novel non-invasive method for the detection of sickle cell anaemia in routine diagnostic use.